The first new antibiotic for UTIs in nearly 30 years has been approved by regulators. Gepotidacin, also known as Blujepa, is ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

Urinary tract infections (UTIs) are increasingly common in men, especially with age, posing serious health risks like blood ...

UTIs are among the most common bacterial infections worldwide, but inappropriate use and overuse of antibiotics is driving ...

A DRUG resistant form of killer fungus is rapidly spreading across the globe and becoming more infectious, scientists warn.

Gynecologists long viewed bacterial vaginosis as solely a women’s issue — until a study that treated their male partners, too ...

For the first time in decades, the US Food and Drug Administration has signed off on new antibiotics to fight gonorrhea. The approvals come at a critical moment: The sexually transmitted infection is ...

The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy ...

The FDA approved gepotidacin (Blujepa), an oral option for the treatment of uncomplicated urogenital gonorrhea among patients ages 12 years and older, GSK announced on Thursday.

Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring ...

Pakistan is facing a growing public health crisis due to the unnecessary use or incomplete doses of antibiotics, with medical ...